- Home
- TMDX vs MAC Comparison
TMDX vs MAC Comparison
Compare TMDX & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMDX | MAC |
|---|---|---|
| Founded | 1998 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.8B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TMDX | MAC |
|---|---|---|
| Price | $141.71 | $18.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 10 |
| Target Price | ★ $144.25 | $19.24 |
| AVG Volume (30 Days) | 660.2K | ★ 1.6M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 3.63% |
| EPS Growth | ★ 170.70 | N/A |
| EPS | ★ 2.54 | N/A |
| Revenue | $566,354,000.00 | ★ $1,099,978,000.00 |
| Revenue This Year | $38.81 | $11.53 |
| Revenue Next Year | $20.49 | $0.20 |
| P/E Ratio | $56.53 | ★ N/A |
| Revenue Growth | ★ 41.20 | 39.55 |
| 52 Week Low | $55.00 | $12.48 |
| 52 Week High | $156.00 | $21.12 |
Technical Indicators
Market Signals| Indicator | TMDX | MAC |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 59.42 |
| Support Level | $134.00 | $17.73 |
| Resistance Level | $151.85 | $18.85 |
| Average True Range (ATR) | 6.57 | 0.48 |
| MACD | 1.73 | -0.05 |
| Stochastic Oscillator | 68.91 | 79.92 |
Price Performance
Historical ComparisonAbout TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.2 million square feet of gross leasable area and averaged $849 sales per square foot over the 12 months ended in June 2025.